{"disease":{"id":"childhood-alveolar-rhabdomyosarcoma","name":"childhood alveolar rhabdomyosarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00354835","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01614795","title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}